William Blair Analysts Increase Earnings Estimates for DVAX

Dynavax Technologies Co. (NASDAQ:DVAX) – William Blair boosted their FY2024 EPS estimates for shares of Dynavax Technologies in a note issued to investors on Monday, January 13th. William Blair analyst M. Phipps now expects that the biopharmaceutical company will post earnings of $0.16 per share for the year, up from their prior forecast of $0.15. The consensus estimate for Dynavax Technologies’ current full-year earnings is $0.19 per share.

Several other brokerages also recently weighed in on DVAX. StockNews.com raised shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Tuesday. HC Wainwright lifted their target price on Dynavax Technologies from $29.00 to $31.00 and gave the stock a “buy” rating in a report on Tuesday.

Dynavax Technologies Price Performance

Shares of Dynavax Technologies stock opened at $12.48 on Wednesday. The company has a 50-day simple moving average of $12.76 and a two-hundred day simple moving average of $11.65. The stock has a market capitalization of $1.64 billion, a PE ratio of 96.01 and a beta of 1.34. Dynavax Technologies has a 52-week low of $9.74 and a 52-week high of $14.41. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23.

Institutional Trading of Dynavax Technologies

A number of large investors have recently made changes to their positions in the stock. Rhumbline Advisers boosted its holdings in Dynavax Technologies by 1.8% in the second quarter. Rhumbline Advisers now owns 310,805 shares of the biopharmaceutical company’s stock worth $3,490,000 after purchasing an additional 5,379 shares during the last quarter. Choreo LLC purchased a new position in shares of Dynavax Technologies in the 2nd quarter worth $363,000. State of New Jersey Common Pension Fund D bought a new stake in shares of Dynavax Technologies in the second quarter worth $1,811,000. WINTON GROUP Ltd increased its position in Dynavax Technologies by 9.3% during the second quarter. WINTON GROUP Ltd now owns 82,403 shares of the biopharmaceutical company’s stock valued at $925,000 after acquiring an additional 7,025 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in Dynavax Technologies by 2.2% in the second quarter. Renaissance Technologies LLC now owns 2,478,178 shares of the biopharmaceutical company’s stock valued at $27,830,000 after acquiring an additional 53,600 shares during the period. 96.96% of the stock is currently owned by institutional investors.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.